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Abstract
 Background—Amongst the challenges to improving care for depressive and anxiety disorders 
(the common mental disorders, CMD) in developing countries are the shortage of skilled human 
resources and the lack of availability of psychosocial interventions. The MANAS trial was 
implemented to test the effectiveness of a lay health worker led intervention in primary health care 
settings to improve outcomes of people with CMD in Goa, India.
 Method—Cluster randomised trial with primary care facility as unit of randomisation. Twenty-
four primary care facilities, with an equal proportion of public Primary Health Centres (PHC) and 
private General Practitioners (GP) practices, were randomly allocated within pre-defined strata, to 
intervention (collaborative stepped care, CSC) or control (enhanced usual care, EUC) groups. All 
adults presenting at a facility were screened for CMD with the General Health Questionnaire and 
those scoring above a cut-off point of five were regarded as eligible for participation in the trial. 
The CSC arm provided case management and psychosocial interventions, delivered by a trained 
Lay Health Counsellor, antidepressant medication by the primary care physician and supervision 
by a visiting mental health specialist. The primary outcome was recovery from ICD-10 defined 
CMD six months after recruitment. The secondary outcome was the severity of symptoms of 
depression and anxiety. Secondary analyses were stratified by facility type (public vs private).
 Results—2796 (81% of the eligible population) were recruited (1360 in the CSC arm and 
1436 in the EUC arm), of whom 1160 (85%) and 1269 (88%) respectively completed the outcome 
evaluation at the primary end-point of six months. Patients with ICD-10 definite CMD in the 
intervention arm were more likely to have recovered at 6 months (65% vs 53%; risk ratio=1.22, 
95%CI 1.00–1.47; risk difference=12%, 95%CI 2%-23%). Secondary analyses showed that the 
intervention had a generally strong and consistent effect in PHC facility attenders but not GP 
facility attenders for all diagnostic groups apart from depression where no effect was found.
 Implications—The MANAS trial is the largest effectiveness trial of a primary-care based 
intervention to integrate CMD treatments into routine primary care in a developing country. The 
trial demonstrates that an intervention led by a trained lay counsellor improves recovery from 
CMD, in particular among those attending primary health care facilities.
 Study Registration—The MANAS project was registered with the National Institutes of 
Health sponsored clinical trials registry and has been assigned the identifier: NCT00446407
 Background
Depressive and anxiety disorders are the leading neuropsychiatric cause of the global burden 
of disease[1], and are associated with an increased risk of suicide, increased health care 
costs and reduced economic productivity [2–5]. Although these disorders are classified as 
Patel et al. Page 2
Lancet. Author manuscript; available in PMC 2016 July 28.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
separate diagnostic categories in ICD-10[6], the broader category of common mental 
disorders (CMD)[7] is often used to describe them as a group because of the high level of 
co-morbidity and similarities in epidemiological characteristics and treatment 
responsiveness[7–10]. The majority of persons with CMD seek healthcare in primary care 
settings[1] where recognition is poor, with fewer than one third of clinically significant cases 
detected[11]. Primary care doctors tend to prescribe a range of medications for patients with 
CMD[12]; mainly tranquilizers (benzodiazepines) and vitamins[13].
A recent systematic review of the constituents of complex, collaborative care interventions 
which improve effectiveness for CMD management in primary care found that the use of 
routine screening, the professional skills of staff and specialist supervision predicted a 
favourable outcome[14]. Although evidence of the efficacy of antidepressants and brief 
psychological treatments has long been available, including trials from developing 
countries[15–18] [19], there are several obstacles to scaling up efficacious interventions to 
the ‘real-world’ primary care context in developing countries[20–22]. These comprise the 
low recognition rate of CMD by primary care doctors[23]; the inadequate use of evidence-
based medications, including antidepressants and the frequent use of non evidence-based 
medications[24]; the inadequate use of psychosocial treatments; and low adherence with 
treatments (ref). Although training programmes for health workers often show an increase in 
knowledge, the improvement in recognition rates are transient[23], and translation to 
improved clinical outcomes has not been evaluated[21, 25].
The Manas project systematically developed an intervention for CMD which sought to 
address these barriers in routine primary health care in Goa, India [26]. Task shifting is an 
increasingly advocated method to address specialist health human resource shortages [27–
28]. Community or lay health workers carry out functions related to health care delivery, 
trained in the context of the intervention and having no formal professional education.[29] 
The aim of the MANAS trial was to evaluate the effectiveness of a lay health counselor 
(LHC) led collaborative stepped care interventions for CMD in two types of primary health 
care settings. The intervention included psychoeducation and support by a lay health 
counselor supplemented by antidepressant Pharmacotherapy, structured psychotherapy, 
and/or psychiatric consultation. More than half of all primary care consultations in India 
take place in the private sector [30] and MANAS aimed to test the effectiveness of the 
intervention in both types of facilities.
 Design And Methods
 Setting
The trial was conducted in Goa, a state in West India with a population of 1.4 million. Goa 
has been the setting of studies on the epidemiology and treatment of CMD for eight 
years[15, 31–36]. Manas was implemented by Sangath, a Goan community mental health 
non-governmental organization, in collaboration with the London School of Hygiene & 
Tropical Medicine (LSHTM), the Government of Goa’s Directorate of Health Services, the 
Voluntary Health Association of Goa and private general practitioners.
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 Objective
To evaluate the effectiveness of a LHC led collaborative stepped care (CSC) intervention on 
recovery from CMD in public (government) Primary Health Centre (PHC) and private 
General Practitioner (GP) health care settings
 Design
A randomised design with health facility as the unit of randomisation was chosen to prevent 
contamination between individuals. The trial was conducted in two consecutive phases from 
April 2007 to September 2009. Phase 1 involved 12 PHCs, while Phase 2 was conducted in 
12 GP facilities.
 Sample Size
Our sample size estimates have been described in detail in our protocol [37]. Briefly, we 
assumed: a coefficient of variation of 0.2, prevalence of ICD-10 of 66% among participants 
screened-positive; follow-up of 75% at 6 months. The resulting sample size of 100 screen-
positive participants in 24 clusters provides over 90% power to detect a difference in 
recovery rates of 70% in the CSC arm versus 50% in the EUC control arm, with estimates 
based on earlier efficacy trials in Goa [15] and Chile [17]. There were no planned interim 
analyses or stopping rules. However, the higher rates of ICD10 cases and follow-up rates 
observed during Phase 1 led to a downward re-estimation of the sample sizes in Phase 2 to 
80 screen-positive participants per cluster.
 Selection of Facilities and Randomisation
The sampling frames included all PHC facilities with the space and privacy for LHCs and 
which were not involved in preliminary phases related to intervention development [26, 38]. 
For Phase 1 we collected the details of all the available PHC and larger Rural Medical 
Dispensaries (n=49) and assessed their suitability for inclusion in the trial based on the 
above criteria. 17 facilities met the inclusion criteria of which 12 were randomly selected for 
inclusion in the trial. For Phase 2, we sent out 400 letters to GPs from a list of all registered 
general medical practitioners in the state. However, the response rate was poor (only eight 
GPs responded of whom six were eligible). The research team then visited GPs who had not 
responded (n=60). Thus a total of 68 GPs were visited and assessed for eligibility of which 
43 declined to participate and three did not meet the inclusion criteria. Twelve out of the 
22eligible GP facilities were randomly selected for inclusion in the trialremaining ten. 
Within the PHC sector, facilities were first stratified by presence/absence of a visiting 
psychiatrist (part of the District Mental Health Program being implemented concurrently in 
one district) and then randomised within four strata; amongst those with a visiting 
psychiatrist, busy with approximately 150 patients per day (n=2), and less busy (n=2); and 
among the eight facilities without a visiting psychiatrist, urban (n=4) and rural (n=4). The 12 
GP facilities were randomised within two strata; busy with more than 40 patients per day on 
average (n=7), and less busy (n=5). Facilities were randomly allocated within each stratum 
to either the intervention or control arm using a 1:1 allocation ratio by the trial statistician 
(HW) using the website www.randomization.com.
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 Trial Participants
A trained community worker used the 12 item General Health Questionnaire (GHQ-12) with 
a cut-off score of 5/6 to screen for CMD. This threshold was determined on the basis of the 
psychometric properties of this tool in similar settings [38]. Eligibility criteria for screening 
were: age >17 years, speaking Konkani, Marathi, Hindi, or English, not requiring urgent 
medical attention, not having difficulty with hearing, speaking or cognition which makes 
interviewing difficult, , not already screened in the previous two weeks, and not already 
receiving the intervention. Those who screened positive for CMD and who expected to be 
resident in Goa for the subsequent 12 months were invited to participate in the trial. If the 
patient gave written or verbal consent, a structured clinical diagnostic interview (the Revised 
Clinical Interview Schedule or CIS-R) [39] (see below) was administered to provide a 
baseline assessment of severity and diagnostic categorization. Patients who screened positive 
but did not meet the inclusion criteria were offered the intervention but were not followed-up 
in the trial.
 The Interventions
All interventions were implemented at the individual level within clusters.
 The Collaborative Stepped Care (CSC) Intervention—The formative and piloting 
work leading to the design of the CSC intervention has been described previously [26]. In 
brief, the intervention is based on the stepped-care approach used in a Chilean trial [17] 
which emphasizes that while simple interventions such as psycho-education may be 
provided to all patients, more resource-intensive interventions may be reserved for 
participants who are severely ill or not responding to the simpler interventions. Thus, the 
approach focuses o efficient use of limited resources. The collaborative approach involves 
three key team members: the LHC, the primary care physician and a visiting psychiatrist 
(“clinical specialist”). The locally-recruited LHC had non-health backgrounds and 
underwent a structured two month training course (http://www.sangath.com/sangath/node/
88). The LHC acted as a case-manager for all who screened positive for CMD and took 
overall responsibility for delivering the intervention for all non-drug treatments, in close 
collaboration with the primary care physician and the clinical specialist. The steps of the 
intervention are presented in Table 1 and individual components are briefly described below.
1. Psycho-education provided by the LHC to all patients screened positive 
for CMD focused on educating the person about their symptoms, the 
association of CMD with inter-personal difficulties (derived from the 
initial phase of Inter-personal Psychotherapy (IPT), see below) and the 
need to share emotional symptoms with the doctor and to share personal 
difficulties with caring family members or other key persons in their social 
network. Psycho-education taught patients simple strategies for symptom 
alleviation, for example breathing exercises for anxiety symptoms. 
Encouraging adherence to CMD treatments and providing information 
about social/welfare agencies when required were other key components 
of psycho-education. one
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2. Antidepressants were recommended only for moderate or severe CMD 
(i.e. GHQ score>7) and for those who did not respond to psycho-education 
alone on the basis of routine clinical assessments by the LHC. The 
antidepressant of choice, fluoxetine,?? is not available in state PHCs and 
was provided by the project to integrate with the existing model of free 
medicines prescribed by the PHC doctor. In the GP clinics doctors could 
prescribe antidepressants of their choice which were purchased by patients 
as normal. Once initiated, antidepressants were recommended for a 
minimum of 90 days at an adequate dose (at least 20mg per day of 
fluoxetine or the equivalent). Physicians were given training over half a 
day and a manual. The other key roles of the physicians were to encourage 
patients to meet the LHC, to avoid the use of unnecessary medications 
(such as vitamins) and to provide usual care for any co-existing physical 
health problems.
3. IPT, delivered by the LHC, was the structured psychological intervention 
chosen due to its demonstrated feasibility and effectiveness in another low 
income country [41], and on its focus on interpersonal problems such as 
grief, disputes and role transitions which were common themes in the 
adverse life experiences of participants in earlier research in Goa [42]. A 
minimum of six sessions, with an optimum of eight and a maximum of 12 
sessions, were offered. IPT was reserved only for patients who had 
moderate or severe CMD, and was offered as an alternative to 
antidepressants or in addition to antidepressants for those who did not 
respond to antidepressants.
4. Referral to the clinical specialist was reserved for patients who were 
assessed as high suicide risk at any stage; were unresponsive to the earlier 
treatments; posed diagnostic dilemmas; had significant co-morbidity with 
alcohol dependence; had associated significant other medical problems; or 
for whom the primary care physician requested a consultation. Each 
facility team was supported by a clinical specialist who visited at least 
once a month and was also available for consultation on the phone to 
discuss cases and to assure supervision and quality assurance of the 
program.
Patients could be discharged either in a planned manner (for example, recovered) or 
unplanned (for example, did not return for reviews despite adherence management 
procedures).
 Control intervention - Enhanced usual care control (EUC)—Physicians and 
patients in usual care practices received screening results and were given the treatment 
manual prepared for primary care physicians. They were allowed to initiate treatments of 
their choice.
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 Outcomes
As per the trial protocol[37] (http://clinicaltrials.gov/ct2/show/NCT00446407?
term=MANAS&rank=1), the primary outcome was the proportion recovered from ICD-10 
CMD, and the secondary outcome the severity of symptoms (see following paragraph), 
assessed at six months.
 Measurement
The primary and secondary outcomes were assessed using the CIS-R, a structured interview 
for use by trained lay researchers, which generates two outputs: a ICD-10 diagnosis derived 
from a computer algorithm and a total score reflecting the overall severity of symptoms [39]. 
The CIS-R is one of the most widely used measures of CMD globally with extensive prior 
use in the study setting [15, 34, 43]. Research assessors underwent two weeks training in the 
use of the interview and quality assurance including using hand-held PDAs to collect data.
 Masking
Masking of the research assessor was maximized by: carrying out evaluations at home; 
randomly allocating unique patient IDs so that there was no association between the ID 
number and the facility identity; outcome evaluation being carried out by an independent 
institution whose team was not privy to the randomization allocation; and carrying out the 
primary outcome assessment prior to all other assessments.
 Process evaluation
Process indicators assessing the fidelity and quality of the CSC intervention were obtained 
from four sources: the separate clinical records maintained by the LHC and the clinical 
specialist; antidepressant use from the clinic records; and quality assessments carried out for 
each component of the intervention. Quality assessments for intervention components were 
made by direct observation or through transcripts of sessions and were rated by senior 
clinicians. The only possible process indicator in the EUC arm was antidepressant use.
 Statistical methods
All analyses were conducted in Stata 11.0. Baseline comparability was assessed for 
individuals who did not consent to be part of the trial, and of participants who did not 
complete review assessments. Comparability of participants in the two arms was assessed 
for potential confounding factors, notably: age, sex, education, severity of CIS-R scores and 
ICD-10 diagnostic distribution. The primary analyses compared participants in their original 
assigned groups, regardless of adherence to the intervention. Patients were divided into four 
diagnostic groups based on their clinical diagnosis at baseline:
1. ICD-10 CMD cases assessed using the CIS-R - the primary analysis 
group.
2. Screen positive cases assessed using the GHQ-12.
3. Sub-threshold cases – patients who screened positive for CMD on the 
GHQ but who did not meet ICD-10 diagnostic criteria for CMD on the 
CIS-R.
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4. ICD-10 depression cases assessed using the CIS-R.
As per the trial protocol [37], the primary analysis was the difference across arms in the 
proportion of ICD-10 cases at baseline who recover at six months. Secondary analyses were 
also evaluated at six months and comprised the differences across arms in: the proportion of 
depression cases who recover; the prevalence of ICD-10 CMD among screen positive cases 
and sub-threshold cases; and the mean total CIS-R score in each diagnostic groups.
Analyses were based on cluster-level summary measures, as individual-level regression 
methods do not perform robustly when there are relatively few clusters per arm, especially 
for stratified cluster randomized trials [44]. For binary outcomes, the impact was measured 
by the risk ratio (RR) and risk difference (RD). The stratum-specific risk ratios were 
calculated as the ratio of the geometric mean risks between arms for each of the six strata, 
and the overall RR was estimated as the weighted-average of these stratum-specific risk 
ratios. An approximate variance for the log(mean risk) in each arm was obtained from the 
residual mean square from a two-way analysis of variance of community log-risk on strata 
and study arm. A 95% confidence interval (CI) for the RR was calculated from this variance 
using a stratified t-test with 12 degrees of freedom [44]. Similarly, a 95%CI for the RD was 
obtained from an analysis of variance of the mean risk on strata and study arm. For 
continuous outcomes (CIS-R score), the measure of effect was the mean difference between 
arms, and these were analysed in an analogous method based on mean scores in each 
facility. As there were no substantial baseline imbalances of key covariates, the primary 
analyses did not adjust for potential confounders. Secondary planned analyses examined the 
impact of the intervention separately in the two types of facilities, with assessment of effect-
modification of the intervention effect by facility type [45]. Sensitivity analyses included 
adjustment for factors imbalanced at baseline.
 Ethics
Details of trial protocol approval and consent have been published previously [Trials paper].
 Results
 Participant flow
(Figure 1): One GP cluster was replaced by a back-up within a month because of small 
patient numbers. All 24 clusters were followed to the end of the trial. Altogether 20,352 
patients were screened, of whom 3,816 (18.8%) screened positive for CMD and 3,434 were 
eligible to participate. Of these, 2,796 (81%) consented to participate and were enrolled 
(1,360 in CSC arm and 1,436 in the EUC arm). Participants who did not consent tended to 
be slightly younger and have more severe CIS-R scores than those who consented. A total of 
1,160 participants in the CSC arm (85%) and 1,269 (88%) in the EUC arm completed the six 
month outcome evaluation. Reasons for loss to follow up were refusal (n=241; 121 in the 
CSC arm and 120 in the EC arm), emigration (n=46; 27, 19), unable to locate (n=67; 45, 
22), death (n=9; 3, 6) and other (n=4; 4, 0). Participants who were not followed up at six 
months were more likely to be younger and male. However there were no differences in 
terms of intervention arm, facility type or baseline diagnostic group (Web Table 1).
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There were 1,098 ICD-10 cases at baseline in the CSC arm (81% of screened positives), and 
1,144 (80%) in the EUC arm. Of these, 944 (86%) of CSC arm participants and 1,017 (89%) 
of EUC arm participants were seen at the six month outcome evaluation. The coefficient of 
variation (k) for CMD prevalence at baseline among all screen positive cases was 0.08, 
indicating relatively little intra-cluster correlation (ICC=0.03).
 Study population
Table 2 shows the socio-demographic and clinical characteristics of the two arms. The trial 
population was predominantly female (82%), with mean age 46.3 years (SD 13.3 years). Of 
the 2,242 ICD-10 cases at baseline (81%), 774 (35%) were depression cases. In general, 
there was good balance between arms; although participants in the EUC arm were more 
likely to have depression, the proportion of ICD-10 CMD cases and mean CIS-R scores 
were similar.
 Impact of the intervention
 Recovery in ICD-10 cases: (Table 3; Figure 2)—There was modest evidence of an 
effect of the intervention on recovery from ICD-10 cases at six months (proportion 
recovered: 65.0% vs. 52.9% in CSC and EUC arms respectively; RR=1.22, 95%CI 
1.00,1.47). The effect was larger among PHC participants (65.9% vs. 42.5%, RR=1.55, 
95%CI 1.02,2.35) but not GP participants (64.1% vs. 65.9%, RR=0.95, 95%CI 0.74, 1.22, p-
value for effect-modification=0.001). However, there was little evidence of an effect of the 
intervention on recovering from CMD among depression cases (RR=1.05, 95%CI 
0.81,1.36).
Results for recovery from CMD were similar when adjusted for available baseline data (age, 
sex, diagnostic category and education; adjusted RR =1.16, 95%CI 0.98-1.38).
 Prevalence of ICD-10 CMD among screen positive cases and sub-threshold 
cases (Table 4; Figure 2)—There was modest evidence of an effect on prevalence of 
ICD-10 at six months among screen positive cases, with a halving of prevalence in PHCs 
(RR=0.54, 95%CI 0.34, 0.81) but no effect in GP facilities (p-value for effect-
modification=0.003). Among sub-threshold cases, there was evidence of a protective effect 
of the intervention overall, and this did not differ by facility type.
 Severity of psychiatric symptoms at six months (Table 5)—For each diagnostic 
group, the mean CIS-R score was lower in the CSC than the EUC arm. Further, in the 
screen-positive cases, ICD-10 cases and depression cases, the intervention had a strong 
effect in PHCs and no effect in GP facilities (p-value for effect modification<0.001).
including imputation using …..
 Process indicators (Table 6)
Table 6 shows process indicators overall and by type of facility. The original target for 
coverage was reached for most indicators, although among patients receiving IPT the 
proportion who completed at least 6 session was lower than expected. This led to a 
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modification of how IPT was used in Phase 2 in the GP facilities, in which IPT was reserved 
as step three treatment for patients not improving with ADT, and components of IPT were 
integrated with the psycho-education. Over half of all patients had a planned discharge from 
the program. These process indicators show that, apart from the IPT, the intervention was 
delivered with high fidelity to the original protocol. The number of quality assessments also 
exceeded the targets set for the trial (detailed results available from corresponding author).
 Adverse events—There were a total of seven serious adverse events (three deaths and 
four suicide attempts) in the CSC arm compared with 12 in the EUC arm (six deaths and six 
suicide attempts).
 Discussion
The Manas trial is the largest evaluation of the effectiveness of a lay health worker led 
intervention for any mental disorder. The primary analysis showed that overall there was 
some evidence of an effect of the intervention on recovery from ICD-10 cases of CMD at six 
months, with and a clear -type effect in PHCs but no effect in GP private facilities. In 
keeping with this finding secondary analyses showed that the intervention had a consistent 
effect in PHC but not GP for all baseline diagnostic groups included apart from depression.
These findings support the primary hypothesis that a LHC led intervention improves 
recovery rates among CMD patients, although only among those attending PHCs. The 
observed effects may under-estimate the true effect as two key components of the 
intervention (screening of all patients and provision of screening results and evidence-based 
guidelines to the patient and physician) were offered in both arms. Neither would be 
available in routine care. The prevalence of outcomes was generally similar in both arms of 
GP facilities and the CSC arm of the PHC facilities. Indeed, the recovery rates in these three 
arms are similar to those reported by other trials (ref) and to our originally hypothesis [37]. 
Thus, it appears that GPs perform well irrespective of presence of a LHC, and as well as 
PHCs with a LHC was available. In contrast, PHCs benefit from the addition of a LHC, and 
the intervention was effective at preventing CMD as well as treating it, as seen by the benefit 
found among sub-threshold cases.
There are several possible explanations for the good performance of the EUC GP facilities in 
the trial. First, the style of GP interactions with patients may be modified once they obtained 
the diagnosis of CMD through screening,. After this they may have offering care similar to 
the LHCs (e.g. better continuity of care same treating physician, more privacy in the office, 
or longer consultations?). In contrast, in the PHCs, large numbers of patients tend to be seen 
for short periods by a given doctor and the privacy required to discuss interpersonal 
difficulties, is not assured. Second, there may be specific therapeutic ingredients in GP 
consultations which deserve inclusion in the intervention to enhance its effectiveness; we 
will be exploring these hypotheses through our qualitative interviews with GPs and 
participants. Third, there were differences in patient characteristics by clinic type (see Web 
Table 2). Patients attending PHCs had poorer socio-economic indicators than those attending 
GP facilities. Finally, whereas the PHC facilities were representative of the typical PHC 
having been selected randomly from the eligible sampling frame, the GP facilities were a 
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highly selected group and likely to represent a sub-group of highly motivated physicians 
who were eager to improve the quality of care for CMD in their clinics. The lack of an 
overall effect among the subgroup of depression patients may be partly due to lower power 
to detect a clinically significant effect in this sub-group, and inadequate intensity of the 
treatments, in particular the failure to deliver IPT as planned.
Trial strengths include: large samples drawn from rural and urban populations and including 
both government and private facilities; high follow-up rates; high levels of fidelity and 
quality of the intervention (with the exception of IPT this reads like the quality of IPT 
delivery was low, which was not the case ); and consistent demonstration of impact in PHCs 
for each diagnostic group apart from depression. In addition, we were able to confirm the 
high specificity of our screening procedure in a ‘real-world’ context. Around 13% of 
patients were not seen at the 6 month outcome, and these were more likely to be younger 
and male. However, separate models by age group and sex were fitted, and showed no 
evidence of differential recovery rates by gender or age. It is therefore unlikely that this 
missing data affects the results.
In light of our findings, we recommend that the intervention be extended to clinics run by 
government facilities. which constitute the majority of clinics? and are likely to be 
influenced by state policies. Screening is feasible because of the high prevalence of CMDs 
in primary care attenders, the brevity of screening instruments[47] and increasing literacy 
rates in many countries which makes self-completion feasible. Screening may have been a 
critically important component accounting for the impressive outcomes in the control GP 
facilities. Those acting as recruited as LHCs could perform several roles, are were relatively 
low-cost and readily available in most developing countries. However, the fact that the 
intervention had no effect at all on the sub-group of patients with depression also indicates 
the need for more intensive treatments for these patients, for example greater emphasis on 
the delivery of the structured psychological treatments or more aggressive 
pharmacotherapy[48].
In conclusion, the Manas trial has demonstrated the effectiveness of a lay health counsellor 
led collaborative stepped care intervention for CMD in primary health care facility attenders 
in India. This evidence should be used to scale-up services for common mental disorders in 
settings where mental health professionals are scarce.
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Figure 1. Participant flow chart
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Figure 2. Effect of intervention on baseline diagnostic groups
a) Proportion of ICD10 cases who recovered at 6 months (n=1961) b) Proportion of 
depression cases who recovered at 6 months (n=673) c) Prevalence of CMD at 6 months 
among screen positive cases (n=2429) d) Prevalence of CMD at 6 months among sub-
threshold cases (n=468)
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Table 2
Baseline characteristics of trial participants, by arm
Intervention arm
CSC EUC
Clusters=12 Clusters=12
N=1360 N=1436
n   % n   %
Facility type
PHC   823   (61) 825   (57)
GP   537   (39) 611   (43)
Baseline diagnostic category
Sub-threshold case   262   (19) 292   (20)
ICD-10 case   1098   (81) 1144   (80)
Depression case (including co-morbid with anxiety)   304   (22) 470   (33)
CIS-R score (mean, SD) 19.9  (9.1)    19.4 (9.1)
Age
18-29 years   147   (11) 147   (10)
30–39 years   296   (22) 275   (19)
40-49 years   365   (27) 368   (26)
50-59 years   256   (19) 278   (19)
over 60 years   296   (22) 368   (26)
Sex
Male   246   (18) 245   (17)
Female   1114   (82) 1191   (83)
Marital status 1
Never married   96   (8) 63   (5)
Married   761   (64) 857   (65)
Widowed   330   (28) 378   (29)
Separated/divorced   8   (1) 18   (1)
Ethnicity 1
Goan   1139   (95) 1262   (96)
Non-Goan   55   (5) 54   (4)
Language 1
Konkani   1173   (98) 1303   (99)
Other   23   (2) 13   (1)
Education 1
<1 year   493   (41) 664   (50)
1-4 years   222   (19) 200   (15)
>=5 years   478   (40) 451   (34)
1
These variables were asked at the 2 month follow-up and are based on 2491 (89%) of participants: 1186 (87%) of those in the CSC arm and 1305 
(91%) in the EUC arm
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Table 6
Process indicators for the intervention facilities
Process indicator Original benchmark Trial performance
PHC phase GP phase Weighted average 
(95% confidence 
interval)
Proportion of screen positive patients who meet ICD-10 criteria 
for CMD
Minimum 66% 78% 84% 81 (79-83)
Proportion of patients who receive at least first psychoeducation 
session
Minimum 90% 95% 98% 96 (95-97)
Proportion of moderate-severe cases who receive antidepressants Minimum 80% 83% 88% 85 (82-88)
Proportion of all patients who receive ADT NA 48% 64% 54 (51-57)
Proportion of patients receiving antidepressants who complete at 
least 3 months treatment
Minimum 50% 53% 52% 53 (49-56)
Proportion of moderate-severe cases who receive IPT NA 5% <1% -
Proportion of patients receiving IPT who complete at least 6 
sessions
Minimum 50% 33% nil -
Proportion of patients who had a planned discharge Minimum 60% 51% 67% 57 (54-60)
Proportion of patients referred to psychiatrist Maximum 5% <1% <1% 0.5 (0.3-1.1)
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Web Table 1
Characteristics of participants reviewed and not reviewed at 6 months
Attended 6 month review
No Yes
N=367 N=2429
n % n % p-value1
Intervention arm
CSC 200 (15) 1160 (85)
EUC 161 (12) 1269 (88) 0.101
Age (years)
18-29 years 66 (18.0) 228 (9.4)
30-39 years 77 (21.0) 494 (20.3)
40-49 years 91 (24.8) 642 (26.4)
50-59 years 63 (17.2) 471 (19.4)
Over 60 years 70 (19.1) 594 (24.5) 0.000
Sex
Male 97 (26.4) 394 (16.2)
Female 270 (73.6) 2035 (83.8) 0.000
Facility type
PHC 232 (63.2) 1416 (58.3)
GP 135 (36.8) 1013 (41.7) 0.129
Baseline diagnostic category
Sub-threshold case 86 (23) 468 (19) 0.173
ICD-10 case 281 (77) 1961 (81) 0.173
Depression case 101 (28) 673 (28) 0.834
1
P-value is likelihood ratio test of contribution of the variable to the model from a logistic regression adjusted for clinic to account for clustering.
Lancet. Author manuscript; available in PMC 2016 July 28.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Patel et al. Page 24
Web Table 2
Characteristics of respondents by type of facility
Facility type
PHC GP
Clusters=12 Clusters=12
N=1648 N=1148
n % n % p-value2
Age
18-29 years 202 (12.3) 92 (8.0)
30-39 years 383 (23.2) 188 (16.4)
40-49 years 439 (26.6) 294 (25.6)
50-59 years 292 (17.7) 242 (21.1)
over 60 years 332 (20.2) 332 (28.9) 0.000
Sex
Male 319 (19.4) 172 (15.0)
Female 1329 (80.6) 976 (85.0) 0.002
Marital status 1
Never married 102 (7.0) 57 (5.4)
Married 965 (66.6) 653 (61.6)
Widowed 367 (25.3) 341 (32.1)
Separated/divorced 16 (1.1) 10 (0.9) 0.002
Ethnicity 1
Goan 1374 (94.8) 1027 (96.9)
Non-Goan 76 (5.2) 33 (3.1) 0.007
Language 1
Konkani 1431 (98.7) 1045 (98.4)
Other 19 (1.3) 17 (1.6) 0.336
Education 1
<1 year 653 (45.1) 504 (47.6)
1-4 years 271 (18.7) 151 (14.3)
>=5 years 525 (36.2) 404 (38.2) 0.042
Baseline diagnostic category
Sub-threshold case 341 (21) 213 (19) 0.094
ICD-10 case 1307 (79) 935 (82) 0.094
Depression case 470 (29) 304 (27) 0.1954
1
These variables were asked at the 2 month follow-up and are based on 2491 (89%) of participants: 1186 (87%) of those in the CSC arm and 1305 
(91%) in the EUC arm
2
P-value is likelihood ratio test of contribution of the variable to the model from a logistic regression adjusted for clinic to account for clustering.
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